CLVRR
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Clever Leaves has been rated Neutral with a band defined by moderate conviction, placed at a 3 out of 5 score. The rating is primarily driven by the company's regulatory standing, where it scores well, marking it as the strongest pillar in the overall assessment. This strength in compliance and regulatory positioning offsets the weaker performance seen in the fundamentals and editorial exposure, contributing to the composite score of 37.9. The market pillar remains minimally analyzed due to the absence of quoted data, leaving it less informative in the current evaluation.
Underlying financial metrics reveal several areas of concern, most notably with revenue growth and margins. Clever Leaves has experienced a modest year-over-year revenue increase, yet it suffers from a severely negative operating margin, signaling operational inefficiencies. Despite achieving a positive gross margin, the net income remains submerged in red, amplified by a stretched cash condition marked by significant burn rates. Primary regulatory filings and licensed fundamentals data provide insights suggesting limited flexibility, with the financial condition reflecting a comprehensive cautionary note.
Looking ahead, the company's activities within the Latin American regulatory environment serve as the crucial catalyst. The jurisdictional stance in this region, supported by a non-existent enforcement history over recent periods, underpins professional confidence in its regulatory path forward. Observers should focus on any shifts in regulation within these jurisdictions, as these will have a material impact on Clever Leaves’ future capabilities and potential for growth within the cannabis sector. Monitoring upcoming filings and regulatory developments will be essential to understanding potential shifts in the Neutral rating position.
- IR / PR agency
- Gateway Group, Inc. (Gateway Investor Relations)
- IR email
- info@cleverleaves.com
- IR page
- Investor relations
- Phone
- +1-201-565-3345
- CEO
- Andres Fajardo
- CFO
- Henry R. Hague III (Hank Hague)
- SEC CIK
- 0001819615
- Website
- Company website
- Market cap
- $0.0M
- Enterprise value
- $-4.7M
- EV / EBITDA
- -0.07
- Revenue (TTM)
- $17.4M
- Gross profit (TTM)
- $6.6M
- EBITDA
- $-13.2M
- Operating margin
- -105.9%
- Profit margin
- -102.8%
- Rev growth YoY
- 5.4%
- Return on equity
- -61.3%
- Return on assets
- -23.4%
- EPS (TTM)
- $-2.11
- Wall St. target price
- $24.00
- Shares outstanding
- 1.8M
- Beta
- 1735.91
- Full-time employees
- 296
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for CLVRR (CLVRR)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for CLVRR (CLVRR), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CLVRR are maintained by Cannabis Investor News and refreshed throughout the trading day.